Syra Health Seeks Shareholder Approval for Significant Equity Plan Expansion
SYRA has more than doubled off its 52-week low of $0.052 on light trading volume (0.1× avg).
Summary
Syra Health Corp. filed its definitive proxy statement, seeking shareholder approval for the election of directors, auditor ratification, and a significant expansion of its equity incentive plan, which could result in over 23% potential dilution.
Key Events · Corporate Governance and Compliance · SYRA
-
Annual Meeting Scheduled
Shareholders will convene on July 23, 2026, to vote on key corporate governance matters, including director elections and auditor ratification.
-
Equity Incentive Plan Expansion Proposed
The company seeks to amend its 2022 Omnibus Equity Incentive Plan to increase the total number of Class A shares available for issuance to 4,100,000.
-
Significant Potential Dilution
If all 4,100,000 shares authorized under the expanded plan were issued, it would represent approximately 23.64% dilution to the current outstanding shares (including Class B equivalent).
-
Routine Governance Proposals
Shareholders will also vote on the election of five directors and the ratification of M&K CPAS, PLLC as the independent registered public accounting firm for fiscal year 2026.
Analysis · SYRA · Trade & Services
Syra Health Corp. is asking shareholders to approve a substantial increase in its 2022 Omnibus Equity Incentive Plan, raising the total shares available for awards to 4,100,000 Class A shares. While intended to attract and retain talent, this authorization represents a potential dilution of approximately 23.64% if all these shares were issued, which is a significant overhang for existing shareholders, especially for a company with a market capitalization of approximately $6.0 million. This proposal follows the company's recent announcement of its first profitable quarter, which could be seen as management leveraging improved sentiment to secure future compensation flexibility.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.5% of the 1626 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SYRA was trading at $0.50 on OTC in the Trade & Services sector, with a market capitalization of approximately $6M. The 52-week trading range was $0.05 to $0.70. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.